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Introduction
Allogeneic hematopoietic cell transplantation is an established treatment for acute myelogenous leukemia (AML). 1 Myeloablative conditioning (MAC) regimens prior to allogeneic transplantation is believed to control leukemia by combining intensive preparative therapy with the benefit of the graft versus leukemia effect. Transplantation of grafts from an HLA-matched sibling has generally been considered to be the treatment of choice for children with AML in first complete remission (CR1). 2 However, with the improved results now obtained with chemotherapy alone, and the known short and long-term risks of allogeneic hematopoietic cell transplantation, this treatment option is no longer offered to all children with AML in CR1, but is reserved for those with intermediate or high-risk disease. [3] [4] [5] Transplantation of grafts from unrelated donors in CR1 is being explored in children with high-risk cytogenetics 6 and is widely offered for those with recurrent leukemia. 7, 8 In recent years, reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation have been demonstrated to be safe and efficacious for adult hematologic malignancies. 9 Low regimen related toxicity and morbidity have dramatically extended the availability of allogeneic hematopoietic cell transplantation to a large and important group of patients previously ineligible by virtue of age or organ dysfunction. RIC regimens depend upon intensive immunosuppression in order to establish donor-recipient chimerism, which rapidly develops into full-donor chimerism with withdrawal of immunosuppression or donor lymphocyte infusion (DLI). Disease control is believed to be afforded principally by graft versus leukemia effects, and to a lesser extent by the chemotherapy administered during conditioning for transplantation. As most RIC regimens use relatively low doses of
For personal use only. on December 25, 2017. by guest www.bloodjournal.org From chemotherapy, transplant related morbidity and mortality are low. A recent summary of the European experience that compared MAC and RIC regimens and for unrelated donor transplantation for adults concluded that RIC regimens were associated with higher relapse risks in patients with AML who were younger than 50 years of age, and lower non-relapse mortality in those older than 50 years. The overall result was leukemia-free survival that was similar with either conditioning regimen, regardless of patient age. 10 Another study from N. American also showed similar outcomes. 11 The results of a phase II trial of RIC transplantation concluded that favorable outcomes could be achieved for children and adolescents with hematologic malignancy in remission at transplantation.
12
Although that trial used a uniform transplant conditioning regimen (busulfan, fludarabine and anti-thymocyte globulin), patients with a variety of hematologic malignancies were eligible and enrollment was limited to 47 patients. Another recent report that examined the role of RIC regimens for malignant and non-malignant diseases confirmed low transplant-related mortality but high graft failure in recipients of umbilical cord blood transplantation. 13 While these reports confirm RIC regimens are well tolerated, there are few reports that have compared transplant-outcomes after RIC regimens to that after MAC regimens in children for specific diseases. The Center for International Blood and Marrow Transplant (CIBMTR) reported outcomes after RIC regimens for pediatric acute lymphoblastic leukemia. 14 In that report, transplant-related mortality and relapse rates were high with a modest 3-year leukemia-free survival rate of 30%. In the current analyses, also using data reported to the CIBMTR, we compared transplant-outcomes after RIC regimens to an appropriately matched population of transplant recipients who received MAC regimens for treatment of children with AML.
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Patients and Methods

Data Collection
The CIBMTR is a voluntary working group of more than 450 transplantation centers that contribute detailed data on consecutive allogeneic and autologous transplantations to a Statistical Recipients of RIC regimens (cases) were matched to recipients of MAC regimens (controls).
Cases were matched for age at transplant ± 6 years, disease status, cytogenetic risk, graft type
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Sixty-seven cases-controls were matched within 6 months of their ages; 28 cases-controls were matched within 6 -12 months of their ages; 21 cases-controls within 1 to 2 years and the remaining 15 cases-controls were matched within 3 -5 years of their ages.
Thirty-nine recipients of RIC transplants (cases) were matched to 141 recipients of MAC transplants (controls). Thirty-one of 39 cases were matched to 4 controls; 2 cases were matched to 3 controls; 5 cases were matched to two controls and 1 case was matched to 1 control. Eightynine transplant centers contributed patients with most centers (n=79) contributing fewer than 5 patients to the study population. The remaining 10 centers each contributed between 5 and 9 patients. As expected most centers contributed only transplants that utilized MAC regimens (n=60), 13 centers contributed only transplants that utilized RIC regimens and the remaining 16 centers contributed both transplants that utilized both RIC and MAC regimens.
Outcomes
The primary endpoint was leukemia-free survival, defined as alive and in complete remission. Death from any cause or relapse was considered an event (treatment failure). Other outcomes studied include: neutrophil recovery, defined as achieving absolute neutrophil count ≥ 0.5 x 10 9 /L for three consecutive measurements, platelets
9 /L without transfusions for 7 days; grade 2 -4 acute graft-versus-host disease (GVHD) 16 ; chronic GVHD 17 ; transplantrelated mortality defined as death not attributed to relapse and relapse, defined as morphologic recurrence of leukemia. Surviving patients were censored at last follow-up and death from any cause was considered an event.
Statistical Methods
The chi-square statistic was used to compare the characteristics of the two treatment groups. The Kaplan-Meier estimate was used to calculate the probabilities of leukemia-free and overall survival. 18 The cumulative incidence estimator was used to calculate the probabilities of neutrophil and platelet recovery, acute and chronic GVHD, TRM and relapse. 19 For neutrophil and platelet recovery and acute and chronic GVHD, death without the event was the competing risk. For transplant-related mortality, relapse was the competing event and for relapse, transplant-related mortality the competing event. Stratified Cox regression models were built to test the relative efficacy of RIC regimens compared to MAC regimens. 20 Cases and controls were matched on age, disease status at transplantation, cytogenetic risk, graft type and transplant period. Other variables tested in the multivariate models include: performance score (90 -100 vs. < 90), recipient cytomegalovirus serostatus (positive vs. negative), donor type (HLA-matched sibling vs. matched unrelated donor vs. mismatched unrelated donor) and GVHD prophylaxis (cyclosporine-containing vs. tacrolimus-containing). Variables that attained a level of significance of 0.05 or less were considered significant. There were no first order interactions.
P-values are two sided. All analyses were performed in SAS 9.3 (Cary, NC).
Results
Patient, disease and transplant characteristics
Patients, diseases and transplant characteristics are shown in Table 1 . Thirty-nine transplantations used RIC regimens and 141 MAC regimens. Conditioning regimens are described in Table 2 . Although a variety of regimens were used, about half of MAC transplant
For personal use only. on December 25, 2017. by guest www.bloodjournal.org From recipients received TBI-containing regimens and the remaining, non-TBI regimens. Busulfan with cyclophosphamide was the most frequently used non-TBI regimen. Only about 20% of RIC regimens included low dose TBI with most patients receiving regimens including alkylating agents and fludarabine. The median age of patients included in both treatment groups was 14 years. In vivo T-cell depletion was equally likely in both groups (49% for RIC regimens compared to 42% for MAC regimens, p=0.39). Although the characteristics of the two treatment groups were largely similar, there were differences. Recipients of RIC regimens were more likely to report poor performance score at transplantation (80 or lower), and were less likely to receive allografts from HLA-matched siblings compared to recipients of MAC regimens.
Additionally, recipients of RIC regimens were more likely to have had a significant fungal infection prior to transplantation, 15 (38%) versus 24 (17%) after MAC regimens (p=0.01).
Considering unrelated donor transplants, recipients of RIC regimens were more likely to receive allografts from HLA-matched donors compared to recipients of MAC regimens. For unrelated donor transplantation, HLA-match considered allele-level HLA typing at HLA-A, -B, -C and -DRB1. For umbilical cord blood transplantation, HLA-matching considered low resolution match at HLA-A and -B and allele-level at -DRB1. There were no differences in GVHD prophylaxis regimens between the two treatment groups, and cyclosporine-containing regimens were more commonly used than tacrolimus-containing regimens in both cases and controls.
Interestingly, there were no differences in the proportion of patients that received RIC and MAC regimens by transplant period (2000-2004 vs. 2005-2009, p=0 .37). The median follow-up of surviving patients was 5 years and 4 years after RIC and MAC transplants, respectively. In this registry study, we had limited ability to determine why a RIC or MAC regimen was selected for 1 0 a particular child. We sought to assess whether certain transplant centers had a preference for one preparative regimen or the other, using the frailty model to look for a transplant center effect and found none (p=0.49).
Outcomes
The unadjusted probabilities of transplant-outcomes are shown in Table 3 . There were no significant differences between treatment groups in the probabilities of hematopoietic recovery, acute and chronic GVHD, transplant-related mortality, relapse, leukemia-free and overall survival after RIC and MAC transplants. These observations were confirmed in multivariate analysis and the results are presented in Table 4 . After adjusting for patient age, disease status at transplantation, cytogenetic risk, graft type and transplant period, the only factor associated with relapse, leukemia-free and overall survival was performance score. The 5-year probabilities of relapse after RIC and MAC regimens in patients with good performance scores were 21% (95% CI 8 -39) and 34% (95% CI 25 -43) respectively (p=0.17). The corresponding probabilities of relapse in patients with poor performance scores were 77% (95% CI 44 -92) and 50% (95% CI 29 -68), p-value=0.08 ( Figure 1A) . The 3-year probabilities of leukemia-free survival were 58% (95% CI 33 -77) after RIC regimens and 54% (95% CI 44 -63) after MAC regimens in those with good performance score, (p-value=0.74). The corresponding probabilities of leukemia-free survival in those with poor performance scores were and 15% (95% CI 2 -39) and 21% (95% CI 8 -39), p=0.67 ( Figure 1B ).
Overall 20 of 39 recipients of RIC transplantation and 69 of 141 recipients of MAC transplantation are dead. In both groups, recurrent leukemia was the predominant cause of death 1 1 accounting for 75% of deaths in the RIC group and 65% of deaths in the MAC group. Death from infections was slightly more prevalent after MAC regimens compared to RIC regimens (19% vs. 10%). In contrast to the MAC group were 2 patients died from GVHD, there were no deaths attributed to GVHD in the RIC group.
Discussion
In this report we describe and compare transplant outcomes for patients younger than 18 years with AML who received either RIC or MAC conditioning regimens for their allogeneic hematopoietic cell transplantation. Notably, we show that, relapse rates are not higher after RIC regimens compared to MAC regimens and that MAC regimens are not associated with higher transplant-related mortality compared to RIC regimens. Currently, MAC conditioning regimens are considered the standard of care for allogeneic hematopoietic cell transplantation in children and adolescents with AML. 1, 2, 7 Yet, the current analyses, albeit in a carefully controlled but non-randomized analysis of a modest number of patients suggest both transplant conditioning strategies are acceptable. Previously, the use of high dose chemotherapy has been considered a potential benefit in disease ablation, raising the concern that relapse will be more frequent if less intense transplant conditioning regimens are used. When RIC regimens were introduced more than a decade ago, studies demonstrated less peri-transplant morbidity and mortality with these regimens, allowing transplantation of older and sicker patients. 21, 22 Some studies in adults have confirmed higher relapse rates with RIC regimens, but lower transplant-related mortality that offsets this disadvantage. 10, 11 In children, transplant-related mortality is generally lower after allogeneic transplantation, potentially reducing the advantage of a RIC regimen should relapse rates be higher with this approach. In this study we saw no increase in relapse rates with the use
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An important limitation of this registry study is the lack of information regarding the rationale for the selection of a RIC regimen. We can only speculate that patients who received RIC were either treated on an institutional protocol or judged to be at high risk for transplantrelated mortality by the treating physician. Indeed, in this study patients receiving RIC regimens had significantly worse performance score, which may partly explain the selection of the RIC regimen. Moreover, prior fungal infections were more common in recipients, supporting this possibility. It is important to also recognize that the sample size of the RIC cohort was small, and the preparative strategy varied, likely limiting power to see smaller differences in outcomes.
Interestingly, RIC regimens were selected for some patients in CR1, maybe due to low performance score and co-morbidities, and also for patients with relapse or induction failure. We performed a controlled analysis, matching recipients of RIC transplantation to those who received MAC transplantation on age, disease status, cytogenetic risk, graft type and transplant period known prognostic factors, to attempt to reduce the impact of this heterogeneity on the analysis.
In adults RIC regimens are generally associated with lower transplant-related mortality relative to dose-intensive conditioning. 21, 22 However, we observed comparable transplantrelated mortality rates after MAC regimens in our cohort implying regimens with higher intensity are well tolerated in young patients. There are some important limitations to our study and caution must be used in interpreting these data based on a small sample size of retrospective data. We were unable to test for the co-morbidity index of these patients, as these data were not 1 3 collected consistently during the study period. Others have shown the presence of co-morbidities have an adverse effect on survival in the pediatric population and there is no reason to believe that this is not applicable to the current analyses. 23, 24 In the current analyses we used performance score as a surrogate for co-existing morbidities and confirm that scores less than 90 are associated with higher relapse risks and consequently lower leukemia-free and overall
survival. An additional benefit of the use of a RIC preparative regimen might be preservation of fertility and reduced risk of SMN. Our follow-up is short and we are unable to address these important issues in this study.
Our observations support embarking on a carefully controlled randomized trial to establish the role of RIC regimens in this population. In fact, in adults, the results of observational studies comparing RIC and MAC regimens for AML and myelodysplastic syndrome has led to a national trial in the U.S., through the Blood and Marrow Transplant Clinical Trials Network. c For unrelated donor transplantation, HLA-match considered allele-level HLA typing at HLA-A, -B, -C and -DRB1. For umbilical cord blood transplantation, HLA-matching considered low resolution match at HLA-A and -B and allele-level at -DRB1.
Matched unrelated in RIC group: cord blood, n=1; bone marrow, n=7; peripheral blood, n=10.
Matched unrelated in MAC group: cord blood, n=1; bone marrow, n=14; peripheral blood, n=13.
Mismatched unrelated in RIC group: cord blood, n=11; bone marrow, n=3; peripheral blood, n=2.
Mismatched unrelated in MAC group: cord blood, n=42; bone marrow, n=18; peripheral blood, n=13.
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